Breaking News

NeuroBo Signs Exclusive License Agreement with MTHERA for NB-01

Agreement allows MTHERA to conduct research and clinical trials for the future commercialization of NB-01.

Author Image

By: Charlie Sternberg

Associate Editor

NeuroBo Pharmaceuticals Inc., a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, has signed an exclusive license agreement providing MThera Pharma Co., Ltd. (MTHERA) with the rights to NB-01 for the treatment of painful diabetic neuropathy. The agreement allows MTHERA to conduct research and clinical trials, including, but not limited to, a potential Phase 3 clinical trial in the United States and South Korea, for the future commercialization of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters